Stock Events

Stock Events

Lakefront Biotherapeutics NV 

$30.39
230
+$0.00+0% 19:59 Today

Statistics

Day High
28.53
Day Low
27.16
52W High
37.78
52W Low
26.62
Volume
286,745
Avg. Volume
154,819
Mkt Cap
2B
P/E Ratio
3.18
Dividend Yield
-
Dividend
-

Upcoming

Earnings

10AugExpected
Q3 2024
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q1 2026
Next
-3.6
-2.3
-1
0.3
Expected EPS
-0.79964071844
Actual EPS
N/A

Financials

-2.62%Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
3.02BRevenue
-79.04MNet Income

Analyst Ratings

33.00Average Price Target
The highest estimate is 33.00.
From 1 ratings within the last 6 months. This is not an investment recommendation.
Buy
0%
Hold
100%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow GLPG. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Vertex Pharmaceuticals
VRTX
Mkt Cap134.02B
Vertex Pharmaceuticals is a direct competitor in the cystic fibrosis market, where both companies are developing treatments.
Gilead Sciences
GILD
Mkt Cap162.98B
Gilead Sciences collaborates with Galapagos on filgotinib but also competes in other areas of biopharmaceuticals, including antiviral drugs.
Abbvie
ABBV
Mkt Cap461.26B
AbbVie competes in the immunology space, particularly in treatments for rheumatoid arthritis, where Galapagos also has interests.
AMGEN
AMGN
Mkt Cap201.93B
Amgen competes in the biotech space, focusing on innovative therapeutics, including areas like inflammation where Galapagos is active.
Regeneron Pharmaceuticals
REGN
Mkt Cap68.59B
Regeneron Pharmaceuticals is involved in developing treatments for conditions like asthma and arthritis, directly competing with Galapagos' pipeline.
Biogen
BIIB
Mkt Cap31.91B
Biogen competes in the area of biopharmaceuticals with a focus on neurodegenerative diseases, an area Galapagos has shown interest in.
Novartis
NVS
Mkt Cap305.1B
Novartis competes across a broad range of therapeutic areas, including those targeted by Galapagos, such as autoimmune diseases.
Pfizer
PFE
Mkt Cap138.61B
Pfizer operates in various therapeutic areas, including inflammation and immunology, competing with Galapagos' research and development efforts.
Merck
MRK
Mkt Cap319.99B
Merck & Co. competes in the pharmaceutical and biotech sectors, focusing on innovative treatments that could overlap with Galapagos' interests.
Astrazeneca
AZN
Mkt Cap302.65B
AstraZeneca competes in multiple areas, including respiratory diseases, where Galapagos also focuses its research efforts.

About

Lakefront Biotherapeutics NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667, which is in a phase 2 clinical trial in dermatomyositis and systemic lupus erythematosus; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in a phase 1/2 trial in relapsed/refractory non-hodgkin lymphoma; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma. The company has collaboration agreements with Gilead Sciences, Inc. The company was formerly known as Galapagos NV and changed its name to Lakefront Biotherapeutics NV in May 2026. The company was incorporated in 1999 and is headquartered in Mechelen, Belgium.
Show more...
CEO
Mr. Henry Gosebruch
Employees
452
Country
Belgium
ISIN
US36315X1019

Listings

BR
BE
LKFT.BR
AS
NL
LKFT.AS
SA
BR
LKFT34.SA
MU
DE
GXE.MU

0 Comments

Share your thoughts

FAQ

What is Lakefront Biotherapeutics NV stock price today?▼
The current price of GLPG is $30.39 USD — it has increased by +0% in the past 24 hours. Watch Lakefront Biotherapeutics NV stock price performance more closely on the chart.
What is Lakefront Biotherapeutics NV stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Lakefront Biotherapeutics NV stocks are traded under the ticker GLPG.
Is Lakefront Biotherapeutics NV stock price growing?▼
GLPG stock has risen by +2.37% compared to the previous week, the month change is a +8.61% rise, over the last year Lakefront Biotherapeutics NV has showed a +5.41% increase.
What is Lakefront Biotherapeutics NV market cap?▼
Today Lakefront Biotherapeutics NV has the market capitalization of 2B
When is the next Lakefront Biotherapeutics NV earnings date?▼
Lakefront Biotherapeutics NV is going to release the next earnings report on August 10, 2026.
What were Lakefront Biotherapeutics NV earnings last quarter?▼
GLPG earnings for the last quarter are 0.24 USD per share, whereas the estimation was -0.94 USD resulting in a +125.77% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Lakefront Biotherapeutics NV revenue for the last year?▼
Lakefront Biotherapeutics NV revenue for the last year amounts to 3.02B USD.
What is Lakefront Biotherapeutics NV net income for the last year?▼
GLPG net income for the last year is -79.04M USD.
How many employees does Lakefront Biotherapeutics NV have?▼
As of July 06, 2026, the company has 452 employees.
In which sector is Lakefront Biotherapeutics NV located?▼
Lakefront Biotherapeutics NV operates in the Health & Wellness sector.
When did Lakefront Biotherapeutics NV complete a stock split?▼
Lakefront Biotherapeutics NV has not had any recent stock splits.
Where is Lakefront Biotherapeutics NV headquartered?▼
Lakefront Biotherapeutics NV is headquartered in Mechelen, Belgium.